## Why Celgene Stock Is Not Trading Today
Celgene stock is not trading today due to a pending merger with Bristol-Myers Squibb. The merger was announced on January 3, 2019, and is expected to close in the third quarter of 2019.
Once the merger is complete, Celgene shareholders will receive $50 in cash and one share of Bristol-Myers Squibb stock for each share of Celgene stock they own. Bristol-Myers Squibb shareholders will own approximately 69% of the combined company, while Celgene shareholders will own approximately 31%.
The merger is expected to create a leading biopharmaceutical company with a diversified portfolio of products and a strong pipeline of new drugs. The combined company will have a market capitalization of approximately $140 billion.
In the meantime, Celgene stock is not trading on any exchanges. Shareholders who wish to sell their shares will need to wait until the merger is complete.
## What This Means for Investors
Investors who own Celgene stock will need to decide whether to hold onto their shares or sell them before the merger is complete. Those who hold onto their shares will receive the cash and stock consideration described above. Those who sell their shares will receive the current market price for Celgene stock.
The decision of whether to hold or sell Celgene stock depends on a number of factors, including the investor’s individual circumstances and investment goals. Investors should consult with a financial advisor to make the best decision for their situation.
## Frequently Asked Questions
**Q: Why is Celgene stock not trading today?**
A: Celgene stock is not trading today due to a pending merger with Bristol-Myers Squibb.
**Q: When will Celgene stock start trading again?**
A: Celgene stock is expected to start trading again after the merger with Bristol-Myers Squibb is complete. The merger is expected to close in the third quarter of 2019.
**Q: What will happen to my Celgene shares once the merger is complete?**
A: Celgene shareholders will receive $50 in cash and one share of Bristol-Myers Squibb stock for each share of Celgene stock they own.
**Q: Should I hold onto my Celgene shares or sell them before the merger is complete?**
A: The decision of whether to hold or sell Celgene stock depends on a number of factors, including the investor’s individual circumstances and investment goals. Investors should consult with a financial advisor to make the best decision for their situation.
## Additional Resources
* [Celgene Investor Relations](https://investor.celgene.com/)
* [Bristol-Myers Squibb Investor Relations](https://www.bms.com/investors.html)
* [Securities and Exchange Commission](https://www.sec.gov/)
* [Financial Industry Regulatory Authority](https://www.finra.org/)